Shares of Gilead Sciences Inc. surged over 4% in premarket trading on Wednesday following a solid fourth-quarter earnings ...

Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through sex by 99% and among injectable drug ...

The latest MP to publicly reveal they are living with HIV says the stigma about the virus is putting straight people at risk.

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

But now, that progress is at risk. The recent pause in United States foreign assistance poses a direct threat to the lives ...

Globally about 3.5 million people used PrEP in 2023, up from 200,000 in 2017 but short of the United Nations' 2025 target of ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

The United States eventually did, creating PEPFAR, arguably the most successful foreign aid program in history. HIV, which causes AIDS, is now manageable, though there is still no cure.

Sign up for Capital B Atlanta’s free weekly newsletter and get the untold stories of the 404 delivered to your inbox: ...

GSK has upgraded its long-term sales target after demand for its HIV and oncology drugs lifted the pharma giant to a better-than-anticipated fourth quarter. The FTSE 100 group is now targeting ...

This decision comes as the country’s National Program for the Control of STIs-HIV-Hepatitis revealed its 2024 investment of US$11,493,557.15, benefiting 76,257 individuals living with HIV. The ...

Human immunodeficiency virus (HIV) is a virus that attacks the body's immune system. HIV is a manageable chronic condition. With treatment, people living with HIV can have long and healthy lives.